PRAXIS PRECISION MEDICINES, INC. Deferred Tax Assets, Operating Loss Carryforwards
PRAXIS PRECISION MEDICINES, INC. (PRAX) had Deferred Tax Assets, Operating Loss Carryforwards of $170.16 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-19
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $170.16M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $90.11M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $74.53M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $60.05M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $170.16M 10-K · filed 2026-02-19 |
| 2024-12-31 | $90.11M 10-K · filed 2026-02-19 |
| 2023-12-31 | $74.53M 10-K · filed 2025-02-28 |
| 2022-12-31 | $60.05M 10-K · filed 2024-03-05 |
| 2021-12-31 | $56.48M 10-K · filed 2023-02-07 |
| 2020-12-31 | $26.44M 10-K · filed 2022-02-28 |
| 2019-12-31 | $14.50M 10-K · filed 2021-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |